BioBridgeXAll companies

Repligen Corp

Biotechnology company · Waltham, Massachusetts, United States · Nasdaq: RGEN

Repligen Corp is a biotechnology company headquartered in Waltham, Massachusetts, United States. Its shares trade on Nasdaq under the ticker RGEN. It has received 7 US government small-business research awards (SBIR/STTR) from health agencies, $1.2 million in total, most recently in 2002. It has reported private securities offerings to the US SEC, most recently $48 million sold in a notice filed in 2019.

Profile compiled from public records. Is this your company? Request a correction or update

Repligen at a glance

Typebiotechnology company
HeadquartersWaltham, Massachusetts, United States
Stock listingNasdaq: RGEN
SEC industryBiological Products, (No Diagnostic Substances)
SEC CIK730272

What does Repligen do?

US government research funding

7 SBIR/STTR small-business research awards from US health agencies, $1.2 million in total (1991 to 2002).

Private fundraising reported to the SEC

2 Form D notices; the most recent reported $48 million sold (2019).

Frequently asked questions about Repligen

Where is Repligen headquartered?

Repligen Corp is headquartered in Waltham, Massachusetts, United States.

What does Repligen do?

Repligen Corp is a biotechnology company. Its SEC industry classification is Biological Products, (No Diagnostic Substances).

Is Repligen a public company?

Yes. Repligen Corp trades on Nasdaq under the ticker RGEN.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Last updated 2026-09-24. Data licences